IRVINE, Calif.–(BUSINESS WIRE)–#ASNKidney—Diality Inc., a medical device company responsible for the development of the Moda-flx™ Hemodialysis System, has announced a panel discussion entitled “Expanding Choice in Hemodialysis” to be held on Friday, October 23 during the American Society of Nephrology’s Kidney Week 2026 in Denver. Expert panelists will discuss clinical evidence pertaining to hemodiafiltration (HDF) and perspectives for successful integration into kidney care in the United States.
“We are delighted to bring together such a distinguished and knowledgeable panel at ASN later this month,” said Dr. Cynthia Silva, MD, vice president medical affairs at Diality. “Their collective expertise from landmark studies such as CONVINCE and MOTHER brings valuable real-world perspective to this conversation, helping shape our understanding of convective clearance and its potential to transform kidney care in the U.S.”
Panelists for this event include Dr. Roberto Pecoits-Filho, Professor Bernard Canaud, and Dr. Matthew B. Rivara.
Dr. Pecoits-Filho, MD, PhD is a Distinguished Research Scientist at Arbor Research Collaborative for Health and an Adjunct Professor in the Division of Nephrology at the University of Michigan. He is a recognized leader in global nephrology initiatives such as the Dialysis Outcomes and Practice Patterns Study (DOPPS) and has authored more than 500 peer-reviewed publications holding an H-index of 92, reflecting the broad impact of his scientific work.
Professor Bernard Canaud, MD, PhD is Emeritus Professor of Nephrology at the Montpellier University School of Medicine in Montpellier, France. He has authored more than 700 peer-reviewed publications and 100 textbook chapters, delivered over 1,800 invited lectures at international scientific meetings, and received numerous distinctions. He is a pioneering expert in the development and worldwide implementation of HDF.
Dr. Matthew Rivara, MD is Professor of Medicine in the Division of Nephrology at the University of Washington School of Medicine, and a practicing nephrologist at Harborview Medical Center in Seattle. His scholarly work has focused on clinical and patient-reported outcomes in dialysis patients. He has authored numerous peer-reviewed publications, informed both clinical practice and health policy, and is recognized for his contributions to nephrology education as an active member of the Faculty for Home Dialysis University.
“Hemodiafiltration has been used internationally for many years, and medium cutoff (MCO) membranes represent another important advancement in dialysis therapy. I look forward to evaluating the evolving evidence for both approaches, with a focus on their respective benefits, limitations, and implications for patients in the United States,” said Dr. Matthew Rivara. “Our shared goal as nephrologists is to advance clinical outcomes, support informed modality choices, and improve quality of life for dialysis patients and their families.”
About Diality
Diality is a medical device company focused on developing solutions to improve lives impacted by kidney disease. The Moda-flx Hemodialysis System is a user-friendly, mobile, and connected hemodialysis platform designed to maximize clinical flexibility by combining prescription capabilities of in-center systems with the ease-of-use of next generation hemodialysis devices. Please visit www.diality.com or find us on LinkedIn to learn more about Diality.
Registered attendees of ASN Kidney Week 2026 can visit https://diality.rsvpify.com/ to RSVP for the event. This activity is not a Continuing Education (CE) activity.
Contacts
MEDIA CONTACT:
Sam Choinski
Pazanga Health Communications
[email protected]
(860) 301-5058
